Pfizer Has Eyes On EU Rituximab Market Following EC Approval

Ruxience Approved For All Indications Of Reference Brand

 
• By Dean Rudge

Pfizer has received European Commission approval for the firm’s Ruxience biosimilar to Roche’s MabThera brand, including as a treatment for rheumatoid arthritis, opening the door to a three-way biosimilar fight in the European Union.

EU_White_Arrow
Pfizer can begin preparations to roll out rituximab in Europe. • Source: Shutterstock

More from Biosimilars

More from Products